** Shares of 89Bio ETNB.O down 6.2% post-market to $8.44 as co looks to raise equity
** ETNB shares closed up ~26% at $9 on Mon, getting a boost after Akero Therapeutics AKRO.O said its lead drug, efruxifermin, showed it can help reverse scarring in patients with type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH). AKRO shares ended session on Mon up 97.5% at $51.71
** After the bell, ETNB commences $250 mln offering comprised of stock and pre-funded warrants to fund its lead candidate, pegozafermin, to treat MASH
** Goldman Sachs, Leerink and BofA lead bookrunners
** Co has ~117.58 mln shares outstanding for ~$1.1 bln market cap, per LSEG
** ETNB shares, which have risen for past six sessions, up 15.1% YTD
** Separately, AKRO launched $300 mln stock offering after the bell
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。